spacer
home > ict > winter 2019 > improving outcomes in diabetes research
PUBLICATIONS
International Clinical Trials

Improving Outcomes in Diabetes Research

Diabetes is often referred to as an epidemic, with an estimated 415 million adults worldwide living with the condition, according to the International Diabetes Federation Diabetes Atlas – approximately 1 in 11 of the adult population (1). What’s more, this figure is expected to rise to 642 million people worldwide by 2040. With a reported 46% of people with diabetes undiagnosed, these figures are, realistically, much higher.

With so much of the population suffering, pharmaceutical companies are continuing to invest in research into this condition in a bid to bring new and improved treatments to market across the globe. With this in mind, this article will discuss the current status of diabetes clinical research. In particular, it will provide an overview of the current diabetes landscape, including the types of disease and condition management, as well as the challenges of clinical research. Putting the person with diabetes at the heart of the development process will demonstrate how sponsors can implement patient-centric electronic data capture solutions which improve the user experience and support better study outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Katie Garner is the Therapeutic Areas Advisor at CRF Bracket. She is responsible for providing specific therapeutic advice and supporting the therapeutic, sales, marketing, and product development teams. Previously, Katie worked as a Project Manager for a health outcomes consultancy and at the NHS Purchasing and Supply Agencies Centre for Evidence-Based Purchasing. She has also worked for the Medicine and Healthcare products Regulatory Agency as a Senior Medical Device Specialist, responsible for the safety and regulation of in vitro diagnostic and contraceptive medical devices.
spacer
Katie Garner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Stevanato Group signs an agreement with Nelson Labs to provide best-in-class Extractables and Leachables testing services at its US Technology Excellence Center

Piombino Dese, Padua Italy and Salt Lake City, USA September 2, 2020: Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated services for combination products, and Nelson Laboratories, LLC, a global provider of lab testing and expert advisory services signed today a partnership agreement that will provide Extractables and Leachables testing at SG US Technology Excellence Center in Boston, MA.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement